Product image of Ondansetron Accord (Ondansetron) supplied by GNH India

Ondansetron Accord

Active Ingredient:
Ondansetron
Origin:
EU

Ondansetron Accord (Ondansetron)

Ondansetron, the active ingredient in Ondansetron Accord, is a 5‑HT3 receptor antagonist presented as an injectable solution for intramuscular and intravenous use. It treats chemotherapy‑induced nausea and vomiting, radiotherapy‑induced nausea and vomiting, postoperative nausea and vomiting, and nausea associated with surgery in adult patients.

GNH India supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Manufacturer / TM Owner

Accord Healthcare Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ondansetron is a selective 5‑HT3 receptor antagonist used to prevent nausea and vomiting across several treatment pathways.

  • Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting in patients receiving emetogenic chemotherapy.
  • Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting caused by radiation therapy.
  • Post‑operative nausea and vomiting: prevents nausea and vomiting after surgical procedures.
  • Surgery‑related nausea and vomiting: used to prevent nausea and vomiting associated with anesthesia and surgical stress.

How It Works

  • Ondansetron works by selectively blocking peripheral and central serotonin (5‑HT3) receptors. This antagonism prevents serotonin from stimulating the chemoreceptor trigger zone in the brain and vagal afferents in the gastrointestinal tract, thereby inhibiting the neural pathways that trigger nausea and vomiting.

Side Effects

Common side effects are generally mild and transient.

Common Side Effects

  • Headache: mild to moderate headache may occur.
  • Constipation: reduced bowel movements are reported.
  • Injection site reactions: pain, erythema, or swelling at the site of administration.

Serious or Rare Side Effects

  • QT interval prolongation: may lead to cardiac arrhythmias.
  • Severe allergic reaction: anaphylaxis or hypersensitivity can occur.
  • Serotonin syndrome: rare but potentially life‑threatening when combined with other serotonergic agents.

Precautions & Warnings

Before initiating therapy, consider the following precautions.

  • Cardiac assessment: evaluate patients with known cardiac disease or prolonged QT interval.
  • Electrolyte monitoring: correct hypokalemia, hypomagnesemia, or hypocalcemia which can exacerbate QT prolongation.
  • Hepatic impairment: use caution and consider dose adjustment in patients with severe liver dysfunction.
  • Hypersensitivity: avoid in individuals with known allergy to ondansetron or other 5‑HT3 antagonists.
  • Drug interactions: review concomitant medications that may affect cardiac rhythm or ondansetron metabolism.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ondansetron may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

  • Apomorphine: concurrent use can cause severe hypotension and loss of consciousness.
  • Other QT‑prolonging agents: co‑administration increases risk of cardiac arrhythmias.
  • Carbamazepine: induces metabolism, reducing ondansetron effectiveness.

Moderate Interactions (Monitor Closely)

  • Aprepitant: may increase ondansetron plasma levels; monitor for enhanced effects.
  • Dexamethasone: combined use may require dose adjustments.
  • Serotonergic agents: monitor for signs of serotonin syndrome.

Frequently Asked Questions

Ondansetron Accord is an injectable antiemetic used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, surgery, and postoperative recovery. It works by blocking serotonin receptors that trigger the vomiting reflex, helping patients maintain comfort and continue essential treatments.

Ondansetron selectively antagonizes peripheral and central 5‑HT3 serotonin receptors. By blocking these receptors in the chemoreceptor trigger zone of the brain and the gastrointestinal vagal afferents, it interrupts the signaling cascade that leads to nausea and vomiting, providing effective relief.

The specific dose and administration schedule for Ondansetron Accord are determined by the prescribing clinician based on the patient’s condition, treatment setting, and clinical guidelines. Healthcare professionals tailor the regimen to achieve optimal antiemetic control while considering safety.

The safety of ondansetron in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ondansetron belongs to the 5‑HT3 antagonist class, offering rapid and effective control of nausea and vomiting with a favorable safety profile compared with older agents such as dopamine antagonists. It is often preferred for chemotherapy‑induced emesis due to its targeted mechanism and lower incidence of extrapyramidal side effects.

Ondansetron Accord should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Maintaining the cold‑chain ensures the stability and potency of the injectable solution throughout its shelf life.

The product is supplied as an injectable solution for intravenous or intramuscular injection. Administration is performed by a qualified healthcare professional, following aseptic technique and the dosing instructions provided by the prescriber.

Serious risks include QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and rare cases of serotonin syndrome when combined with other serotonergic drugs. Patients should be monitored for cardiac symptoms and hypersensitivity signs during therapy.

Ondansetron should be avoided in patients with known hypersensitivity to ondansetron or other 5‑HT3 antagonists, and in those with a history of significant QT prolongation or uncontrolled cardiac arrhythmias. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ondansetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT